We also showed that pharmacological inhibition of RUNX/CBFB activity significantly reduced mouse neurofibroma growth in vivo, implicating a novel signaling pathway involving RUNX1/3 repression of Pmp22 in neurofibroma initiation and/or maintenance. This evidence concerns the gene RUNX1 and neurofibroma.